Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 3/Signature 1
From BugSigDB
Reviewed Marked as Reviewed by Folakunmi on 2024-2-15
Source: Figure 2g
Description: Culturomics-based analyses of fecal samples in 16 Responders and 16 Non-Responders Non-Small Cell Lung Carcinoma patients (defined as the best clinical outcome) before PD-1 blockage immunotherapy, each commensal colony having been identified by mass spectrometry
Abundance in Group 1: decreased abundance in Responders
| NCBI | Quality Control | Links |
|---|---|---|
| Staphylococcus haemolyticus | ||
| Corynebacterium aurimucosum |
Revision editor(s): WikiWorks
